Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
RxSight

RxSight (NASDAQ: RXST) insider transactions

In the twelve months to 10 November 2026, executives and directors of RxSight reported 4 open-market sales of 16,947 shares ($117,951) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in RxSight shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
15 September 2026Weinberg EricSee remarksOption exercise+35,168$4.34235,516Form 4
2 September 2026Weinberg EricSee remarksOpen-market sale−2,041$6.96200,348Form 4
2 September 2026Goldshleger IlyaChief Operating OfficerOpen-market sale−2,041$6.9681,509Form 4
2 September 2026Wilterding MarkChief Financial OfficerOpen-market sale−7,765$6.9625,049Form 4
2 September 2026Kurtz Ronald M MDChief Medical OfficerOpen-market sale−5,100$6.9671,775Form 4
31 August 2026Weinberg EricSee remarksOption exercise+5,370—202,389Form 4
31 August 2026Goldshleger IlyaChief Operating OfficerOption exercise+5,370—83,550Form 4
31 August 2026Wilterding MarkChief Financial OfficerOption exercise+20,441—32,814Form 4
31 August 2026Kurtz Ronald M MDChief Medical OfficerOption exercise+13,425—76,875Form 4
17 June 2026Andrews JulieDirectorGrant or award+37,037—78,076Form 4
17 June 2026Tammenoms Bakker JulietDirectorGrant or award+37,037—85,183Form 4
17 June 2026Cohen Raymond WDirectorGrant or award+30,864—66,532Form 4
17 June 2026Corley Jesse AndersonDirectorGrant or award+37,037—86,227Form 4
17 June 2026Link William J PhdDirectorGrant or award+37,037—74,892Form 4
17 June 2026Fountain TamaraDirectorGrant or award+37,037—72,582Form 4
17 June 2026Maniar ShwetaDirectorGrant or award+37,037—55,172Form 4
17 June 2026Palmisano Robert JDirectorGrant or award+37,037—78,076Form 4
17 June 2026Warner Robert KeithDirectorGrant or award+37,037—78,076Form 4
17 April 2026Goldshleger IlyaChief Operating OfficerOption exercise+12,489$4.1378,180Form 4
28 February 2026Gaines ScottChief Customer OfficerOption exercise+6,261—17,428Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the RxSight page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.